Ambu (Buy, TP: DKK196.00) - Awaiting duodenoscope approval
We believe Ambu is on the verge of receiving FDA approval for its single-use duodenoscope, and we have delved into what we consider its considerable potential. This product is central to the short case, and its approval should support continued short-covering. We have also looked at Ambu’s Visualisation business including the ENT launch, which we conclude got off to a similar start to the aScope 3. We reiterate our BUY and have raised our target price to DKK196 (175).
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.